The recall overhang is partially priced in, but the company's cash position ($30.4M) is dwindling fast against a $14.3M quarterly burn. Traders should focus on the FDA decision timeline for CGuard Prime 80 cm and original CGuard — positive decisions could re-rate the stock, while further delays could force a dilutive capital raise. The cost savings program is a necessary but insufficient step.
Price Chart
Executive Summary
InspireMD's Q2 2026 revenue was essentially flat YoY at $1.77M, missing the $2.1M consensus estimate due to a voluntary U.S. recall of its CGuard Prime 135 cm delivery system that generated $734k in customer credits and an inventory impairment of $612k. The company posted a GAAP net loss of $14.3M ($0.17/share), narrower than the $0.19 consensus estimate, and initiated a cost-saving plan expected to generate $9M in annual savings. The stock faces binary risk ahead of anticipated FDA decisions on CGuard Prime 80 cm and original CGuard later this year.
Key Financial Metrics
Key Facts
- Q2 2026 revenue of $1.77M, flat YoY ($1.78M) and below $2.1M consensus
- U.S. revenue was negative $351k due to $734k in customer credits from voluntary recall of CGuard Prime 135 cm
- International revenue grew 21% YoY to $2.12M
- GAAP net loss of $14.3M ($0.17/share) vs consensus estimate of -$0.19 — beat by 10.5% on EPS, but reflects recall costs
- Gross loss of $774k vs gross profit of $313k in prior year; adjusted gross profit of $572k
- Cash burn: cash + marketable securities fell from $54.2M (Dec 31, 2025) to $30.4M (June 30, 2026) — a drop of $23.8M in 6 months
- Post-quarter cost savings actions initiated, targeting $9M annual savings
- FDA decisions on CGuard Prime 80 cm for TCAR and original CGuard platform still anticipated later in 2026
- CGUARDIANS II trial 30-day outcomes: 100% device success, zero deaths/strokes/MI
- Design changes to CGuard Prime 135 cm delivery system in validation testing; FDA submission expected before year-end
Financial Impact
Revenue miss of $330k vs consensus; recall-related charges of $1.35M ($734k credits + $612k impairment) wiped out Q2 profitability; cash burn rate of ~$4M/month
Risk Factors
- Cash run-rate of ~$4M/month with only $30.4M on hand suggests capital raise likely within 2-3 quarters
- Further FDA delays on CGuard Prime 80 cm or original CGuard could push U.S. re-entry to 2027+
- Recall remediation costs may exceed current estimates if design validation fails or FDA requires additional testing
- Potential product liability or class action lawsuits related to the CGuard Prime recall
- Stock has limited analyst coverage (only 3 analysts) and low liquidity, amplifying volatility
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-038624 |
| Document: form8-k.htm | 0001493152-26-038624 |
| Document: 0001493152-26-038624-index-headers.html | 0001493152-26-038624 |
| Document: 0001493152-26-038624-index.html | 0001493152-26-038624 |
| Document: 0001493152-26-038624.txt | 0001493152-26-038624 |
| 8-K Data (Synthetic) | 0001493152-26-038624 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 21, 2026 5w ago | 8-K | $0.7500 $0.6895 | ▼ −8.07% | ▼ −7.05% | $0.4500 (−40.00%) |
Sep 21, 2026 5w ago | Press Release | $0.7500 $0.6895 | ▼ −8.07% | ▼ −7.05% | $0.4500 (−40.00%) |
Aug 17, 2026 10w ago | 8-K | $0.8798 $0.8699 | ▲ +1.13% | ▼ −0.07% | $0.4500 (+48.85%) |
Aug 17, 2026 10w ago | Press Release | $0.8798 $0.8699 | ▲ +1.13% | ▼ −0.07% | $0.4500 (+48.85%) |
Aug 10, 2026 11w ago | Press Release | $0.8500 $0.8816 | ▲ +3.72% | ▲ +4.12% | $0.4500 (−47.06%) |
Jul 29, 2026 12w ago | 8-K | $0.6718 $0.7222 | ▲ +7.50% | ▲ +3.88% | $0.4500 (−33.02%) |
Jul 23, 2026 13w ago | 8-K | $0.6835 $0.6718 | ▲ +1.71% | ▲ +2.09% | $0.4500 (+34.16%) |
Jul 2, 2026 16w ago | 8-K | $0.6990 $0.7121 | ▲ +1.87% | ▲ +0.94% | $0.4500 (−35.62%) |
May 21, 2026 22w ago | Insider Cluster | $1.00 $0.9900 | ▼ −1.00% | ▼ −2.66% | $0.4500 (−55.00%) |
May 15, 2026 23w ago | Insider Cluster | $1.05 $0.9500 | ▼ −9.52% | ▼ −11.14% | $0.4500 (−57.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers